Showing results (41-50 of 400) with videos related to

Sort By:
Pageof 40
Seminars in Thrombosis and Hemostasis|October 1, 1986
Coagulant versus amidolytic properties of human and bovine thrombins: implications in standardization and diagnostic usageJ Fareed, J M Walenga, L G Svendsen, et al.
Annals of the New York Academy of Sciences|January 1, 1989
Biochemical and pharmacologic inequivalence of low molecular weight heparinsJ Fareed, J M Walenga, D Hoppensteadt, et al.
Expert Opinion on Investigational Drugs|June 1, 1997
Low molecular weight heparins: a developmental perspectiveJ Fareed, D Hoppensteadt, W Jeske, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1985
Studies on the profibrinolytic actions of heparin and its fractionsJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Clinical Chemistry|February 1, 1983
Diagnostic efficacy of newer synthetic-substrates methods for assessing coagulation variables: a critical overviewJ Fareed, H L Messmore, J M Walenga, et al.
Thrombosis Research|December 1, 1991
In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole bloodB Kaiser, J Fareed, J M Walenga, et al.
The American Journal of Cardiology|September 16, 1998
Low-molecular-weight heparins: pharmacologic profile and product differentiationJ Fareed, W Jeske, D Hoppensteadt, et al.
Thrombosis Research|April 27, 2001
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonistS Ahmad, W P Jeske, Q Ma, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndromeS Ahmad, J M Walenga, W P Jeske, et al.
The Annals of Thoracic Surgery|February 1, 1991
Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass modelJ M Walenga, M Bakhos, H L Messmore, et al.
Pageof 40